Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

KIT

Financiado

Kidney Injury Technology

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and eco... ver más

30/04/2015

Bio-inRen

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

Bio-inRen El descubrimiento, desarrollo y venta de productos farmaceuticos y biotecnologicos para el diagnostico y tratamiento de las enfermedades hum...

TRL 7-8 | 123K€

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-04-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

PHC-12-2014-1: Clinical research for the validation of biomarkers and/or diagnostic medical devices

I+D

Cerrada hace 10 años

0% 70% 100%

1 Participantes

Bio-inRen

50.00K€ | Lider

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 6 meses Fecha Inicio: 2014-10-10
Fecha Fin: 2015-04-30

Líder del proyecto

Bio-inRen

TRL 7-8 | 123K€

Presupuesto del proyecto 71K€

Descripción del proyecto Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores